Management Change/Compensation (Form 8-K)

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 24, 2026, Ronald McClurg notified NeuroOne Medical Technologies Corporation (the "Company") of his intention to retire as the Company's Chief Financial Officer. The effective date of Mr. McClurg's retirement as Chief Financial Officer will be June 30, 2026. Following his retirement as an officer, Mr. McClurg will remain employed by the Company as a Senior Advisor, to ensure a smooth transition of duties, until December 31, 2026 (the "Retirement Date").

In connection with Mr. McClurg's retirement, the Board announced that Christopher Volker, the Company's Chief Operating Officer, will succeed Mr. McClurg as the Company's Chief Financial Officer effective as of July 1, 2026. Mr. Volker has extensive experience in the medtech industry, including senior leadership roles at Abbott, Cardiovascular Systems, Inc. ("CSI"), and St. Jude Medical. At CSI, he served as Vice President & General Manager of International and had direct responsibility for international P&L and commercial expansion, including sales, training & education, marketing, business development and program management. Prior to CSI, Mr. Volker held executive leadership roles at St. Jude Medical, including senior roles in corporate finance where he reported directly to St. Jude Medical's Chief Financial Officer.

He began his career in healthcare and technology investment banking, where he developed expertise in financial analysis, mergers and acquisitions, strategic planning, growth equity investments and financings. Mr. Volker earned a Bachelor of Arts degree from St. John's University and a Master of Business Administration in Finance from the Wharton School at the University of Pennsylvania. Mr. Volker holds the Chartered Financial Analyst® designation.

Mr. Volker's base salary will be increased to $350,000 in connection with his appointment as Chief Financial Officer, but the other compensatory and material terms of Mr. Volker's employment with the Company will remain unchanged.

In connection with Mr. McClurg's anticipated retirement, he and the Company entered into a Transition and Release Agreement, dated as of April 28, 2026 (the "Transition Agreement"), pursuant to which Mr. McClurg will continue to receive his current salary and employment benefits until the Retirement Date, at which time his employment with the Company will cease. In exchange for the payments made under the Transition Agreement, Mr. McClurg provides a general release of claims, and agrees to customary restrictive covenants.

The foregoing description of the Transition Agreement is qualified in its entirety by reference to the text of the Transition Agreement. The form of the Transition Agreement is attached as Exhibit 10.1 hereto and incorporated herein by reference.